A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint

被引:0
作者
Qing, Yun [1 ,2 ]
Thall, Peter F. [1 ]
Yuan, Ying [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Biostat & Data Sci, Houston, TX 77030 USA
关键词
Bayesian adaptive design; futility monitoring; go; no-go decision; interim analysis; OPTIMAL 2-STAGE DESIGNS; CLINICAL-TRIALS; SURVIVAL; SAMPLE;
D O I
10.1002/pst.2256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A robust Bayesian design is presented for a single-arm phase II trial with an early stopping rule to monitor a time to event endpoint. The assumed model is a piecewise exponential distribution with non-informative gamma priors on the hazard parameters in subintervals of a fixed follow up interval. As an additional comparator, we also define and evaluate a version of the design based on an assumed Weibull distribution. Except for the assumed models, the piecewise exponential and Weibull model based designs are identical to an established design that assumes an exponential event time distribution with an inverse gamma prior on the mean event time. The three designs are compared by simulation under several log-logistic and Weibull distributions having different shape parameters, and for different monitoring schedules. The simulations show that, compared to the exponential inverse gamma model based design, the piecewise exponential design has substantially better performance, with much higher probabilities of correctly stopping the trial early, and shorter and less variable trial duration, when the assumed median event time is unacceptably low. Compared to the Weibull model based design, the piecewise exponential design does a much better job of maintaining small incorrect stopping probabilities in cases where the true median survival time is desirably large.
引用
收藏
页码:34 / 44
页数:11
相关论文
共 50 条
  • [31] Bayesian decision sequential analysis with survival endpoint in phase II clinical trials
    Zhao, Lili
    Woodworth, George
    STATISTICS IN MEDICINE, 2009, 28 (09) : 1339 - 1352
  • [32] Sample size calculation for randomized selection trials with a time-to-event endpoint and a margin of practical equivalence
    Dehbi, Hakim-Moulay
    Embleton-Thirsk, Andrew
    McCaw, Zachary Ryan
    STATISTICS IN MEDICINE, 2022, 41 (20) : 4022 - 4033
  • [33] A Bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and a time-to-event
    Rizopoulos, Dimitris
    Ghosh, Pulak
    STATISTICS IN MEDICINE, 2011, 30 (12) : 1366 - 1380
  • [34] Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions
    Rufibach, Kaspar
    Grinsted, Lynda
    Li, Jiang
    Weber, Hans Jochen
    Zheng, Cheng
    Zhou, Jiangxiu
    PHARMACEUTICAL STATISTICS, 2023, 22 (04) : 671 - 691
  • [35] Single-Arm Phase II Group Sequential Trial Design With Survival Endpoint at a Fixed Time Point
    Wu, Jianrong
    Xiong, Xiaoping
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2014, 6 (04): : 289 - 301
  • [36] A Review of Statistical Issues with Progression-Free Survival as an Interval-Censored Time-to-Event Endpoint
    Sun, Xing
    Li, Xiaoyun
    Chen, Cong
    Song, Yang
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (05) : 986 - 1003
  • [37] Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its components
    Liao, Ran
    Chakladar, Sujatro
    Gamalo, Margaret
    PHARMACEUTICAL STATISTICS, 2022, 21 (06) : 1342 - 1356
  • [38] Estimation in multi-arm two-stage trials with treatment selection and time-to-event endpoint
    Bruckner, Matthias
    Titman, Andrew
    Jaki, Thomas
    STATISTICS IN MEDICINE, 2017, 36 (20) : 3137 - 3153
  • [39] A Bayesian Phase I/II Trial Design for Immunotherapy
    Liu, Suyu
    Guo, Beibei
    Yuan, Ying
    JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2018, 113 (523) : 1016 - 1027
  • [40] Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting
    Ji, Lingyun
    Alonzo, Todd A.
    CLINICAL TRIALS, 2024, : 131 - 141